Contineum’s test drug may reverse multiple sclerosis damage
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.
HQ Team May 17, 2024: The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages.
A cell therapy currently used to treat blood cancers can lead to clinical studies for ovarian cancer, scientists from one of the world’s.
AstraZeneca, an Anglo-Swedish pharmaceutical company, is set to acquire Neogene Therapeutics, a biotechnology firm, for $320 million